Intravenous insulin therapy during lung resection does not affect lung function or surfactant proteins

Area of Science:

• Anesthesiology
• Pulmonary Medicine
• Endocrinology

Background:

• Major surgeries like lung resection disrupt glucose homeostasis, leading to hyperglycemia.
• Hyperglycemia is a common complication in critical illness and surgical procedures.
• Managing hyperglycemia is crucial for patient outcomes.

Purpose of the Study:

• To investigate the immediate effects of intravenous insulin administration on lung physiology during lung resection surgery.
• To examine insulin's impact on gene transcription, specifically surfactant proteins, in lung tissue.
• To assess the safety and efficacy of intraoperative insulin therapy for hyperglycemia in lung surgery patients.

Main Methods:

• A prospective study involving 64 patients undergoing lung resection.
• Randomized allocation of patients to receive either insulin treatment or standard care during surgery.
• Monitoring of blood gases and analysis of surfactant protein mRNA levels via qPCR in lung tissue samples.

Main Results:

• Intravenous insulin administration during lung resection did not significantly alter blood gas levels (pH, pCO2, pO2, etc.).
• No immediate changes in the mRNA expression of surfactant proteins A1, A2, B, C, and D were observed with insulin treatment.
• The study provides novel insights into the physiological and molecular effects of intraoperative insulin therapy.

Conclusions:

• Short-term intravenous insulin treatment during lung resection surgery does not adversely affect respiratory function or blood gas balance.
• Intraoperative insulin therapy does not appear to impact the immediate expression of key surfactant proteins in lung tissue.
• The findings suggest that carefully managed insulin administration is safe for maintaining breathing quality during and after lung resection.